Gilead Announces Racial Equity Community Impact Fund to Support Black Communities Across United StatesBusiness Wire • 12/09/20
Yescarta® Shows Positive Results as a First-Line Treatment for Patients With High-Risk Large B-cell LymphomaBusiness Wire • 12/06/20
Magrolimab Demonstrates Clinical Responses in Ongoing Phase 1b Trial of Previously Untreated Acute Myeloid Leukemia PatientsBusiness Wire • 12/06/20
Yescarta® Is First CAR T-cell Therapy to Demonstrate High Response Rates and Durable Clinical Benefit in a Pivotal Indolent Non-Hodgkin Lymphoma StudyBusiness Wire • 12/05/20
New Four-Year Data Show Long-Term Survival in Patients With Large B-Cell Lymphoma Treated With Yescarta® in ZUMA-1 TrialBusiness Wire • 12/05/20
New Data for TecartusTM Demonstrate Durable Responses at One Year Follow-Up in Relapsed or Refractory Mantle Cell LymphomaBusiness Wire • 12/05/20
Gilead Sciences, Inc. (GILD) Management Presents at Evercore ISI 3rd Annual HealthCONx (Transcript)Seeking Alpha • 12/02/20
Gilead Canada Announces Notice of Compliance for DESCOVY® (emtricitabine, tenofovir alafenamide) for HIV Pre-Exposure Prophylaxis (PrEP)Business Wire • 12/01/20
Gilead Sciences to Present at the 3rd Annual Evercore ISI HealthCONx Conference on Wednesday, December 2, 2020Business Wire • 11/24/20